Comparison of Hypericum perforatum extract WS 5570 and paroxetine in acute treatment of moderate to severe depression - first results from a randomised multicentre study

2010 ◽  
Vol 9 ◽  
pp. 18-19
Author(s):  
A Szegedi ◽  
R Kohnen ◽  
A Dienel ◽  
M Kieser ◽  
S Klement
Keyword(s):  
Multicentre Study ◽  
Acute Treatment ◽  
Hypericum Perforatum ◽  
Severe Depression ◽  
First Results

Cognitive Therapy Versus Medications: Acute Treatment of Severe Depression

2004 ◽  
Author(s):  
Robert J. Derubeis ◽  
Jay D. Amsterdam ◽  
John P. O'Reardon ◽  
Paula R. Young
Keyword(s):  
Cognitive Therapy ◽  
Acute Treatment ◽  
Severe Depression

Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime

2007 ◽  
Vol 3 (2) ◽  
pp. 171-181 ◽  
Author(s):  
L. HALVORSEN ◽  
F. I. LEE ◽  
I. C. E. WESDORP ◽  
N. J. JOHNSON ◽  
J. G. MILLS ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Acute Treatment ◽  
Reflux Oesophagitis ◽  
Reflux Œsophagitis

First results from the multicentre study Rehabilitation of Occupational Skin Diseases - Optimization and Quality Assurance of Inpatient Management (ROQ)

2011 ◽  
Vol 66 (3) ◽  
pp. 140-147 ◽  
Author(s):  
Christoph Skudlik ◽  
Elke Weisshaar ◽  
Reginald Scheidt ◽  
Peter Elsner ◽  
Britta Wulfhorst ◽  
...  
Keyword(s):  
Quality Assurance ◽  
Multicentre Study ◽  
Skin Diseases ◽  
Occupational Skin Diseases ◽  
First Results ◽  
Inpatient Management

scholarly journals Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study

Rheumatology ◽  
2014 ◽  
Vol 54 (1) ◽  
pp. 157-162 ◽  
Author(s):  
W. Tillett ◽  
G. Shaddick ◽  
A. Askari ◽  
A. Cooper ◽  
P. Creamer ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Multicentre Study ◽  
Work Disability ◽  
Factors Influencing ◽  
First Results

scholarly journals Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.

Gut ◽  
1986 ◽  
Vol 27 (9) ◽  
pp. 1091-1095 ◽  
Author(s):  
F I Lee ◽  
P I Reed ◽  
J P Crowe ◽  
R L McIsaac ◽  
J R Wood
Keyword(s):  
Duodenal Ulcer ◽  
Multicentre Study ◽  
Acute Treatment

A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression

1997 ◽  
Vol 12 (1) ◽  
pp. 34-41 ◽  
Author(s):  
JP Olie ◽  
KP Gunn ◽  
E Katz
Keyword(s):  
Side Effects ◽  
Multicentre Study ◽  
Severe Depression ◽  
Antidepressant Effect ◽  
Major Depressive ◽  
Double Blind ◽  
Continuation Phase ◽  
Double Blind Placebo ◽  
Persistent Pattern ◽  
Continuation Treatment

SummaryIn a double-blind multicentre study of outpatients with DSM-III-R major depressive disorder, 129 sertraline and 129 placebo patients were evaluated over a 6-week period. Sertraline exhibited a significantly greater (P < 0.001) antidepressant effect compared to placebo as measured by the HAM-D, MADRS, CGI-S and CGI-I. In the subset of patients with severe depression (baseline HAM-D ≥ 25), sertraline was also significantly more effective than placebo (P < 0.05). Side effects were more commonly reported in sertraline (59%) compared to placebo (38%) patients; the most common being nausea, headache and insomnia. A subset of 107 patients (66 sertraline; 41 placebo) who were defined as responders (CGI-I of 1 or 2) after 6 weeks treatment were entered into a 20-week continuation phase. In this responder subset, there was continuing improvement in both groups of patients, but with no significant differences in mean HAM-D or MADRS between the groups. However, a higher number of sertraline patients were associated with a persistent pattern of improvement relative to placebo (P < 0.05). The incidence of side effects was similar in sertraline (52%) and placebo (49%) treated patients in the continuation period.

Sign in / Sign up

Export Citation Format

Share Document